Table 7.

Genes that have a general association (P-value < 0.05) with the progression-free glioblastoma survival

Gene Symbol	Probe Identifier	P-value	Hazard Ratio1	Relevant literature references
Pla2g7	206214_at	<.0001	0.11 (0.05-0.23)	[119]O
Pdgfb	216061_x_at	<.0001	0.18 (0.09-0.35)	[28]G
Calm2	207243_s_at	0.0011	0.22 (0.09-0.54)	[28]G
Timp3	201148_s_at	<.0001	0.26 (0.16-0.41)	[26]G
Agpat1	215535_s_at	<.0001	0.27 (0.15-0.51)	n/a
Ifngr1	202727_s_at	<.0001	0.32 (0.19-0.53)	[27]G
Pvr	214444_s_at	<.0001	0.32 (0.19-0.54)	[26]G
Ndufv1	208714_at	0.0002	0.33 (0.19-0.59)	n/a
Fgfr2	211401_s_at	<.0001	0.39 (0.26-0.57)	[26]G
E2f3	203693_s_at	<.0001	0.42 (0.29-0.60)	[28]G
Pold2	201115_at	0.0007	0.43 (0.27-0.70)	[26]G
Calm3	200622_x_at	0.0001	0.43 (0.28-0.67)	[28]G
Tp53	211300_s_at	<.0001	0.43 (0.29-0.64)	[25]G
Raf1	201244_s_at	0.0141	0.46 (0.25-0.85)	[26]G
Pknox2	219046_s_at	<.0001	0.46 (0.33-0.62)	[120]O
App	214953_s_at	0.0016	0.47 (0.30-0.75)	[24]G
Fstl1	208782_at	<.0001	0.47 (0.35-0.62)	[25]G
Camk2b	211483_x_at	0.0008	0.54 (0.38-0.77)	[28]G
Pten	204053_x_at	0.0003	0.60 (0.46-0.79)	[26]G
Mdm2	217373_x_at	<.0001	0.66 (0.57-0.76)	[26]G
Ccnd1	208711_s_at	0.0273	0.80 (0.66-0.98)	[28]G
Hspa1a/Hspa1b	202581_at	0.0529	0.82 (0.67-1. 00)	[24]G
Cd24	208650_s_at	0.0069	0.85 (0.75-0.95)	[121]O
Clec2b	209732_at	0.06452	1.19 (0.99-1.44)	[122]O
Cav2	203324_s_at	0.0024	1.25 (1.08-1.44)	[123]O
Snx10	218404_at	<.0001	1.34 (1.16-1.57)	[124]O
Wee1	215711_s_at	0.0083	1.37 (1.08-1.74)	[27]G
Hras	212983_at	0.08022	1.49 (0.95-2.33)	[85]G
Mns1	219703_at	0.0053	1.51 (1.13-2.02)	n/a
Ppp1r15a	37028_at	0.011	1.54 (1.10-2.15)	n/a
App	211277_x_at	0.08112	1.56 (0.95-2.56)	[24]G
Fadd	202535_at	0.09342	1.57 (0.93-2.65)	[125]O
Pik3r1	212239_at	0.018	1.60 (1.08-2.36)	[20]G
Mmp14	217279_x_at	0.0182	1.66 (1.09-2.52)	[24]G
Mtap	204956_at	0.0016	1.66 (1.21-2.27)	[26]G
Il13ra1	211612_s_at	0.0003	1.72 (1.28-2.32)	[24]G
Kcnj13	210179_at	0.0235	1.74 (1.08-2.82)	[126]O
Clip3	212358_at	0.0022	1.75 (1.22-2.50)	n/a
Aanat	207225_at	0.0114	1.78 (1.14-2.79)	[127]O
Camk2g	214322_at	0.0024	1.86 (1.24-2.78)	[56]G
Prkca	215195_at	0.0005	1.90 (1.32-2.73)	[28]G
Kdm6b	41386_i_at	0.0003	2.03 (1.39-2.96)	n/a
Zfy	207246_at	0.0016	2.06 (1.31-3.22)	[128]O
Smarcb1	212167_s_at	0.0004	2.06 (1.38-3.07)	[26]G
Utp20	209725_at	<.0001	2.08 (1.46-2.98)	n/a
Igl@	211655_at	0.0209	2.22 (1.13-4.38)	[129]O
Atf5	204998_s_at	<.0001	2.31 (1.72-3.11)	[130]G
Shox	207570_at	<.0001	2.66 (1.73-4.07)	[24]G
Loc283079	215929_at	0.0071	2.73 (1.31-5.69)	n/a
Ung	202330_s_at	0.0001	2.79 (1.66-4.68)	[27]G
Hnrnpd	213359_at	<.0001	2.94 (1.91-4.52)	n/a
Camk2b	209956_s_at	<.0001	3.02 (2.13-4.29)	[28]G
Timp3	201150_s_at	<.0001	3.10 (1.88-5.11)	[26]G
Nras	202647_s_at	<.0001	3.93 (2.60-5.95)	[28]G
Paics	214664_at	<.0001	5.28 (3.13-8.91)	[66]O

n/a, No association with any type of cancer found in literature;

¹ Hazard ratio estimate (95% confidence interval);

² Borderline significant (P-value < 0.1) included for completeness;

^G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;

^O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.